**Aurora Diagnostics Announces Sale of Greensboro, N.C., Blood Testing Laboratory to Dominion Diagnostics**

*Sale Allows Aurora to Focus on its Anatomic Pathology Practices;*

*Dominion Diagnostics to Launch Clinical Pathology Division*

**PALM BEACH GARDENS, Fla., and NORTH KINGSTOWN, R.I. –** Aurora Diagnostics, the leading independent specialized laboratory company focused on anatomic pathology, announced today that it has sold its Greensboro, N.C., blood testing clinical laboratory to Dominion Diagnostics, effective December 31, 2014.

Terms of the transaction were not disclosed.

“We are pleased to complete this transaction, which allows us to focus our efforts and resources on our core business of anatomic pathology,” said Daniel D. Crowley, CEO of Aurora Diagnostics. Aurora has entered into a laboratory services agreement with Dominion Diagnostics to perform clinical analysis for Aurora’s Greensboro pathology laboratory.

Dominion Diagnostics, headquartered in North Kingstown, R.I., is a leading, certified and accredited national medical laboratory that provides drug monitoring solutions and actionable clinical information to improve patient care and treatment outcomes in addiction medicine, chronic pain management and other healthcare specialties.

“This successful transaction with Aurora supports our ongoing commitment to advance treatment outcomes and improve patient care,” says Bob Garvey, CEO of Dominion Diagnostics. “The launch of a new clinical pathology division in Greensboro will allow us to meet Aurora’s continued pathology needs and better address the needs of our clients and patients.”

Beyond the expansion into clinical pathology made possible through the Greensboro laboratory acquisition, Dominion Diagnostics will initiate aggressive clinical research and development to launch new products and services that complement and expand upon its core business.

**About Aurora Diagnostics**

Aurora Diagnostics is the leading independent specialized laboratory company focused on anatomic pathology at 23 locations in the United States. Employing over 120 licensed physicians, Aurora Diagnostics provides high-quality diagnostics and testing information for the patients of its primary referral sources—dermatologists, OB/GYN professionals, gastroenterologists, urologists, general surgeons, oncologists, and for more than 60 community hospitals. For additional information regarding Aurora Diagnostics and the services it provides, please visit the company website at [www.auroradx.com](http://www.auroradx.com/).

**About Dominion Diagnostics**Dominion Diagnostics is a leading national laboratory that offers clinical drug testing, prescription monitoring services, and a full suite of clinical support solutions. Since 1997, Dominion Diagnostics has provided services to clients representing a diversity of medical specialties across the United States, including addiction medicine, behavioral health, pain medicine, primary care, psychiatry, and hospital systems. Dominion Diagnostics is supported by a world‐class team that shares a commitment to clinical excellence, compliance, and integrity. For more information, please visit [www.dominiondiagnostics.com](http://www.dominiondiagnostics.com/" \t "_blank).

**Aurora Media Relations Contact:**

Bill Halldin, Halldin Public Relations | (916) 781-0657 | [bill@halldinpr.com](mailto:bill@halldinpr.com)

**Dominion Diagnostics Media Relations Contact:**

Julie Lenahan, Dominion Diagnostics | (401) 578-3326 | [jlenahan@dominiondiagnostics.com](mailto:jlenahan@dominiondiagnostics.com)

***Forward Looking Statements***

*Certain matters discussed in this press release may constitute forward-looking statements within the meaning of federal securities laws. Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors, some of which are not within the control of the Company.  Aurora reports information that may be significant for investors in its filings with the Securities and Exchange Commission (SEC), and Aurora encourages investors to consult those filings.*